Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.
A 24-year-old male experienced an increase in estradiol levels and symptoms like gynecomastia and excessive sweating after using Minoxidil for hair loss. His estradiol levels decreased after he stopped using Minoxidil.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
RU and Pyri block androgenreceptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Fluridil may decrease the number of androgenreceptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
Combining spironolactone with koshine might enhance the effect of blocking androgenreceptors for hair loss treatment. The user suggests adding crushed spironolactone pills to koshine.
A user proposed genetically engineering scalp stem cells to stop androgenreceptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
The user emphasizes hydration, androgenreceptors, and a 7-day ejaculation recovery period for appearance enhancement. They suggest Minoxidil, finasteride, and RU58841 for hair loss, along with a diet rich in animal fats, specific exercises, and fasting.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgenreceptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation discusses using ketoconazole, an anti-androgen, for hair loss and whether mesotherapy with dermarolling could enhance its absorption into the scalp. The user questions if the typical 2% ketoconazole shampoo dose would be effective when used after dermarolling to target androgenreceptors in the scalp.
The conversation discusses GT20029, a drug in Phase II trials that targets androgenreceptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgenreceptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgenreceptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgenreceptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgenreceptors downregulate in androgen deficient environments.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgenreceptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgenreceptors.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgenreceptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
The conversation discusses whether creatine causes hair loss for those using finasteride or dutasteride, with some suggesting creatine might increase DHT or upregulate androgenreceptors, potentially leading to hair loss. Others argue the evidence is not conclusive, citing limited studies and personal anecdotes, with some avoiding creatine as a precaution.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgenreceptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgenreceptors in hair follicles, potentially offering fewer side effects.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgenreceptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgenreceptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgenreceptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgenreceptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgenreceptors in the scalp.
Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, and Nizoral shampoo. Nizoral's effectiveness is debated, with some suggesting it works as a weak antagonist for androgenreceptors, while others attribute its benefits to anti-fungal and anti-inflammatory properties.
The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.